Pemetrexed-induced eyelid edema: incidence and clinical manifestations

Anticancer Res. 2010 Dec;30(12):5185-8.

Abstract

Background: Pemetrexed-induced eyelid edema is a rare side-effect of pemetrexed treatment.

Patients and methods: Retrospective analysis of the incidence and severity of eyelid edema was conducted in patients treated with pemetrexed in a single institution.

Results: Eighty-six patients received pemetrexed-containing chemotherapy either as a single agent (45 patients) or in combination with cis- or carboplatin (41 patients). Two patients (2.3%) with stage IV non-small cell lung cancer (NSCLC) presented the edema typically localized in the lower eyelid after first-line treatment with carboplatin-pemetrexed. The edema remained identical in both patients during treatment and regressed in one patient in whom treatment was withdrawn. No other localizations of edema were observed in these patients.

Conclusion: Pemetrexed-induced eyelid edema may be more frequent than originally reported. The physiopathological mechanism and, as a consequence, the treatment and/or prevention of this apparently benign side-effect remains unknown.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Breast Neoplasms / drug therapy
  • Carboplatin / administration & dosage
  • Carcinoma, Non-Small-Cell Lung / drug therapy
  • Edema / chemically induced*
  • Eyelid Diseases / chemically induced*
  • Eyelids / drug effects
  • Female
  • Glutamates / administration & dosage
  • Glutamates / adverse effects*
  • Glutamates / therapeutic use
  • Guanine / administration & dosage
  • Guanine / adverse effects
  • Guanine / analogs & derivatives*
  • Guanine / therapeutic use
  • Humans
  • Lung Neoplasms / drug therapy
  • Male
  • Mesothelioma / drug therapy
  • Middle Aged
  • Pemetrexed
  • Retrospective Studies

Substances

  • Glutamates
  • Pemetrexed
  • Guanine
  • Carboplatin